Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy

Aurelia H.M. de Vries Schultink; Alwin D.R. Huitema; Jos H. Beijnen

doi:10.1016/j.breast.2018.08.100

Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy

Aurelia H.M. de Vries Schultink^*
, Alwin D.R. Huitema
, Jos H. Beijnen

^*Corresponding author for this work

Clinical Pharmacy

Research output: Contribution to journal › Article › Academic › peer-review

2 Downloads (Pure)

Abstract

Different strategies have been proposed to individualize tamoxifen treatment in order to improve recurrence-free survival in estrogen receptor (ER)-positive breast cancer. To date, the debate remains on which strategy should be used. The objective of this viewpoint is to highlight Therapeutic Drug Monitoring of endoxifen, the active tamoxifen metabolite, as the preferred methodology compared to CYP2D6 genotyping for individualizing tamoxifen therapy for ER-positive breast cancer patients treated in the adjuvant setting.

Original language	English
Pages (from-to)	38-40
Number of pages	3
Journal	The Breast
Volume	42
Early online date	22 Aug 2018
DOIs	https://doi.org/10.1016/j.breast.2018.08.100
Publication status	Published - 1 Dec 2018

Keywords

Endoxifen
Therapeutic Drug Monitoring
Treatment individualization

Access to Document

10.1016/j.breast.2018.08.100

de vries schultink2Final published version, 216 KBLicence: Taverne

Cite this

@article{3bff0be289b749f7aed4905a82378253,

title = "Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy",

abstract = "Different strategies have been proposed to individualize tamoxifen treatment in order to improve recurrence-free survival in estrogen receptor (ER)-positive breast cancer. To date, the debate remains on which strategy should be used. The objective of this viewpoint is to highlight Therapeutic Drug Monitoring of endoxifen, the active tamoxifen metabolite, as the preferred methodology compared to CYP2D6 genotyping for individualizing tamoxifen therapy for ER-positive breast cancer patients treated in the adjuvant setting.",

keywords = "Endoxifen, Therapeutic Drug Monitoring, Treatment individualization",

author = "\{de Vries Schultink\}, \{Aurelia H.M.\} and Huitema, \{Alwin D.R.\} and Beijnen, \{Jos H.\}",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2018",

month = dec,

day = "1",

doi = "10.1016/j.breast.2018.08.100",

language = "English",

volume = "42",

pages = "38--40",

journal = "The Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy

AU - de Vries Schultink, Aurelia H.M.

AU - Huitema, Alwin D.R.

AU - Beijnen, Jos H.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Different strategies have been proposed to individualize tamoxifen treatment in order to improve recurrence-free survival in estrogen receptor (ER)-positive breast cancer. To date, the debate remains on which strategy should be used. The objective of this viewpoint is to highlight Therapeutic Drug Monitoring of endoxifen, the active tamoxifen metabolite, as the preferred methodology compared to CYP2D6 genotyping for individualizing tamoxifen therapy for ER-positive breast cancer patients treated in the adjuvant setting.

AB - Different strategies have been proposed to individualize tamoxifen treatment in order to improve recurrence-free survival in estrogen receptor (ER)-positive breast cancer. To date, the debate remains on which strategy should be used. The objective of this viewpoint is to highlight Therapeutic Drug Monitoring of endoxifen, the active tamoxifen metabolite, as the preferred methodology compared to CYP2D6 genotyping for individualizing tamoxifen therapy for ER-positive breast cancer patients treated in the adjuvant setting.

KW - Endoxifen

KW - Therapeutic Drug Monitoring

KW - Treatment individualization

UR - https://www.scopus.com/pages/publications/85053153224

U2 - 10.1016/j.breast.2018.08.100

DO - 10.1016/j.breast.2018.08.100

M3 - Article

C2 - 30153552

SN - 0960-9776

VL - 42

SP - 38

EP - 40

JO - The Breast

JF - The Breast

ER -

Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this